HomeMarket NewsMicro Cap StocksDisease With Market Estimated At $3.9 Billion Lacks Cure – Will This...

Disease With Market Estimated At $3.9 Billion Lacks Cure – Will This Company Be The First To Find One?

Actionable Trade Ideas

always free

screenshot 2023 09 15 at 11.10.27 pm

GRI BIO GRI is a dynamic clinical-stage biotechnology firm on the forefront of revolutionizing healthcare by groundbreaking scientific developments. The corporate is concentrated on essentially altering how inflammatory, fibrotic and autoimmune ailments are handled.

When the physique’s immune system is working abnormally, it may possibly result in continual irritation that’s extraordinarily damaging. Two of probably the most acknowledged inflammatory ailments are IPF, or Idiopathic Pulmonary Fibrosis, and Lupus. IPF at present has no remedy and its TAM is estimated to be simply shy of $4 billion.

The corporate has a number of promising therapies at present within the growth pipeline that tackle these debilitating ailments.

Study extra right here:

Featured photograph by Hal Gatewood on Unsplash.

This submit accommodates sponsored content material. This content material is for informational functions solely and never supposed to be investing recommendation.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.